Tool Vendors Unworried by Pharma Industry Woes; See Opportunities in Biotech Drugs | GenomeWeb
This story originally appeared in Biocommerce Week, a newsletter that has been discontinued.
 
With a bevy of blockbuster drugs slated to lose patent protection over the next several years and a number of large pharmaceutical players cutting staff, life science instrument vendors could be facing a potential tightening of pharma spending budgets reminiscent of a couple of years ago.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genes involved in histone deacetylation in Arabidopsis, effects of pathogenic presenilin-1 mutations, and more.

After a study finds DNA from antibiotic-resistant bacteria in Beijing smog, residents there worry, according to the New York Times.

Canada begins its search for a chief government science advisor, Nature News reports.

A company is using facial recognition tools to identify genetic disorders from pictures, Technology Review reports.